Nkarta Inc to Discuss NKX101 and NKX019 Clinical Data Call Transcript
Thank you for standing by. Welcome to the Nkarta conference call to review preliminary clinical data for NKX101 and NKX019. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to the company.
Thank you, operator, and good morning, everyone. I'm Greg Mann, Senior Vice President, Public Affairs and Investor Relations at Nkarta. Thank you for joining our call this morning.
Earlier today, Nkarta issued a press release announcing clinical data on 2 programs, NKX101 and NKX019. This press release, today's webcast and corresponding slides are available on our website. We're looking forward to discussing these 2 sets of preliminary results as we advance toward making engineered CAR-NK cell therapy a reality for cancer patients. On the call today from Nkarta are Paul Hastings, President and Chief Executive Officer; Dr. Kanya Rajangam, Chief Medical Officer; and Dr. Nadir Mahmood, Chief Financial and Business
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |